Innovations in Protein Kinase Therapies - PowerPoint PPT Presentation

Slide1 l.jpg
Download
1 / 5

Oncology Stands as the Leading Indication, Accounting for 92% of the Current Protein Kinase Pipeline Status

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.

Download Presentation

Innovations in Protein Kinase Therapies

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Slide1 l.jpg

Innovations in Protein Kinase Therapies – Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology


Slide2 l.jpg

Oncology Stands as the Leading Indication, Accounting for 92% of the

Current Protein Kinase Pipeline Status

Protein kinase drugs in the pipeline for all indications were analyzed throughout their development phases, and it was found that oncology has the highest number of pipeline drugs, accounting for 92% of total indications, followed by central nervous system accounting for 2%, hematological disorders accounting for 1%, immunology accounting for 1%, metabolic disorders accounting for 1%, and others accounting for 3%. Others include indications like cardiovascular, dermatology,

gastrointestinal, genetic disorders, genito urinary system and sex hormones, hormonal disorders, infectious disease, musculoskeletal, ophthalmology, pharmaceuticals and healthcare, respiratory, toxicology and women's health.

The majority of these drugs are in Phase II, followed by Phase I, Phase III and Preclinical. Only 27 molecules are in discovery phase. The pipeline seems to be outsized when compared to the last few years, and is growing strategically with increased focus on protein kinases. In particular, the oncology indication gained a lot of attention, and protein kinases with their specificity took a major

stake in oncology pipeline molecules.

More pharmaceutical companies are focusing on the oncology indication because of the high levels of unmet needs that exist. This is leading to the development of more and more pipeline drugs targeting protein kinases that could address the needs of the market.


Slide3 l.jpg

Pfizer Dominates With Strong Protein Kinase Pipeline Mainly Targeting

Oncology We have studied the top ten companies whose protein kinase pipeline has more than three molecules, and found that the majority of the companies have compounds targeting the oncology indication.

Pfizer takes a major stake of the protein kinase targeting molecule pipeline. It has 127 molecules in pipeline, among which more than 90% of the molecules are targeting various types of cancer. Many of the compounds are combination drugs which show interest in the specificity of the disease type. After Pfizer, the next company with a high number of molecules in the pipeline is Eli Lilly. It has 94

molecules in pipeline, which again contains a majority of targeting molecules for cancer. Other major companies with strong protein kinase targeting drug pipelines are GlaxoSmithKline plc, AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Novartis AG, Exelixis Inc, Boehringer Ingelheim GmbH, Merck and Takeda Pharmaceutical Company Limited

For further details, please click or add the below link to your browser:

http://www.gbiresearch.com/Report.aspx?ID=Innovations-in-Protein-Kinase-Therapies-Significant-Proportion-of-Protein-Kinase-Pipeline-Contains-Small-Molecule-Drugs-That-Target-Oncology&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report


Slide4 l.jpg

The Strategy of Drug Combinations is Going to Play a Significant Role in

Protein Kinase Development Programs

One of the most successful strategies in the oncology market is ‘drug combinations’. It is mainly employed in oncology. The rationale behind adopting the strategy is that cancer can grow using multiple pathways. Therefore, patients need drug combinations which can block all the possible paths through which cancer can expand. If multiple pathways are knocked out, there would be more chance that patients will respond better and live longer.

As combinations become increasingly important in the treatment of cancer, companies are showing willingness to work together so that clinical trials of combinations can start as early as possible.

GBI Research’s new report, “Innovations in Protein Kinase Therapies – Significant Proportion of Protein Kinase Pipeline Contains Small Molecule Drugs That Target Oncology”, provides in-depth analysis of innovations in protein kinase therapies in the current pharmaceutical market. The report analyzes the protein kinase pipelines of pharmaceutical companies by indication and also according to the phase of clinical trial. This report includes protein kinase pipeline profiles of the top 10 pharmaceutical companies based on their pipeline. It gives you a robust idea of the pipeline, innovations in various indications, new strategies employed for innovation, trends in combination drugs and protein kinase targets. This report is


Slide5 l.jpg

built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:

http://www.gbiresearch.com/Report.aspx?ID=Innovations-in-Protein-Kinase-Therapies-Significant-Proportion-of-Protein-Kinase-Pipeline-Contains-Small-Molecule-Drugs-That-Target-Oncology&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

Visit our report store: http://www.gbiresearch.com

For more details contact:

pressreleases@gbiresearch.com

North America: +1 646 395 5477

Europe: +44 207 753 4299

+44 1204 543 533

Asia Pacific: +91 40 6616 6782


  • Login